AU Patent

AU2019275591B2 — 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1 -yl-benzamides as Btk- inhibitors

Assigned to Merck Sharp and Dohme BV · Expires 2020-10-01 · 6y expired

What this patent protects

IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1 YL-BENZAMIDES AS BTK-INHIBITORS Abstract R5 XN N R1 R4 R2 The present invention relates to 6-5 membered fused pyridine ring compounds according to formula (I) or a pharmaceutically acceptable salt thereof or to pha…

USPTO Abstract

IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1 YL-BENZAMIDES AS BTK-INHIBITORS Abstract R5 XN N R1 R4 R2 The present invention relates to 6-5 membered fused pyridine ring compounds according to formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to formula I in the treatment of Brutons Tyrosine Kinase (Btk) mediated disorders.

Drugs covered by this patent

Patent Metadata

Patent number
AU2019275591B2
Jurisdiction
AU
Classification
—
Expires
2020-10-01
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.